IN8bio to Present at Biotech Showcase 2025 in San Francisco
| INAB Stock | USD 0.26 0.01 4.00% |
About 55% of In8bio's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding In8bio Inc suggests that some traders are interested. The current market sentiment, together with In8bio's historical and current headlines, can help investors time the market. In addition, many technical investors use In8bio Inc stock news signals to limit their universe of possible portfolio assets.
In8bio |
NEW YORK, Jan. 06, 2025 -- IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapie
Read at gurufocus.com
 |
In8bio Fundamental Analysis
We analyze In8bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of In8bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of In8bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
In8bio is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
In8bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with In8bio stock to make a market-neutral strategy. Peer analysis of In8bio could also be used in its relative valuation, which is a method of valuing In8bio by comparing valuation metrics with similar companies.
Peers
In8bio Related Equities
| ZURA | Zura Bio | 6.82 | ||||
| CUE | Cue Biopharma | 6.62 | ||||
| LTRN | Lantern Pharma | 2.91 | ||||
| RVPH | Reviva Pharmaceuticals | 2.72 | ||||
| INMB | INmune Bio | 1.77 | ||||
| ANNX | Annexon | 1.94 | ||||
| ANIX | Anixa Biosciences | 2.00 | ||||
| GANX | Gain Therapeutics | 3.18 | ||||
| WVE | Wave Life | 4.06 | ||||
| PYPD | PolyPid | 4.35 | ||||
| PALI | Palisade Bio | 4.90 | ||||
| ALLR | Allarity Therapeutics | 5.08 | ||||
| WINT | Windtree Therapeutics | 7.14 |
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |